Last reviewed · How we verify

NCT03308513

Determination of Risk Factors and Mortality for Pediatric Chronic Critical Illness in Turkey

Completed Last updated 16 September 2020
What this trial tests

trial in Critical Illness in 888 participants. Completed in 31 October 2018.

Timeline
1 November 2017
Primary endpoint
15 January 2018
31 October 2018

Quick facts

Lead sponsorYuzuncu Yil University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment888
Start date1 November 2017
Primary completion15 January 2018
Estimated completion31 October 2018
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Yuzuncu Yil University

Who can join

Under 18, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is predicted that the number of Pediatric Chronic Critical Illness increases similar to adult all over the world. The prevalence of Pediatric Chronic Critical Illness in Turkey is unknown. The investigators aimed to evaluate the etiology, comorbid conditions, demographic data, prevalence, mortality and costs of these patient in intensive care units in Turkey. In this multi-centered study, The investigators will retrospectively review the last 3 year of patients receiving treatment at the Intensive Care Unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Yuzuncu Yil University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03308513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing